Protopic prescribing information revised

The prescribing information for Protopic (tacrolimus) has been revised following an EMEA review of the safety and efficacy of topical calcineurin inhibitors.

Most of the changes are related to minimising the risk of developing malignancies, including cutaneous and other types of lymphomas when using Protopic to treat atopic dermatitis.

It is recommended that Protopic ointment is applied intermittently and not continuously, being discontinued when clearance occurs and re-initiated if symptoms recur.

Protopic should not be used in patients with congenital or acquired immunodeficiencies or in those being treated with immunosuppressants. Similarly, Protopic should not be applied to lesions considered to be potentially malignant or pre-malignant and care should be exercised when applying the ointment to large areas over prolonged periods.

Further information: Astellas Pharma Ltd, Lovett House, Lovett Road, Staines, Middlesex TW18 3AZ. Tel: (01784) 419615.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases